Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)

Steeb, Theresa; Wessely, Anja; Alter, Mareike; Bayerl, Christiane; Bender, Armin; Bruning, Guido; Dabrowski, Evelyn; Debus, Dirk; Devereux, N.; Dippel, Edgar; Drexler, Konstantin; Dücker, P.; Dummer, Reinhard; Emmert, Steffen; Elsner, P.; Enk, Alexander H.; Gebhardt, Christoffer; Gesierich, Anja; Goebeler, Matthias; Goerdt, Sergij; Goetze, Steven; Gutzmer, Ralf; Haferkamp, Sebastian; Hansel, Gesina; Hassel, Jessica C.; Heinzerling, Lucie; Kähler, Katharina C.; Kaume, Kjell M.; Krapf, Wolfgang; Kreuzberg, Nicole; Lehmann, Percy; Livingstone, Elisabeth; Löffler, Harald; Loquai, Carmen; Mauch, Cornelia; Meier, Friedegund; Meißner, Markus; Moritz, Rose K. C.; Maul, Lara Valeska; Müller, Verena; Mohr, Peter; Navarini, Alexander A.; Nguyen, Ahn Van; Pfeiffer, Christiane; Pföhler, Claudia; Posch, Christian; Richtig, Erika; Rompel, Rainer; Sachse, Michael Max; Sauder, Stefanie; Schadendorf, Dirk; Schatton, Kerstin; Schulze, Hans‐Joachim; Schultz, E. S.; Schilling, Bastian; Schmuth, Matthias; Simon, Jan C.; Streit, Markus; Terheyden, Patrick; Thiem, Alexander; Tüting, Thomas; Welzel, Julia; Weyandt, Gerhard; Wesselmann, Ulrich; Wollina, Uwe; Ziemer, Mirjana; Zimmer, Lisa; Zutt, Markus; Berking, Carola; Schlaak, Max; Heppt, Markus V.

doi:10.1007/s00432-020-03450-0

Cited by 3 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reporting bias in studies of UM cannot be excluded due to specialty-specific care of these patients. While patients with primary UM are treated by ophthalmologists and radiation oncologists, treatment of mUM is usually performed by medical or dermatological oncologists (31). Thus, close interdisciplinary follow-up and therapy is a prerequisite for optimal care and surveillance of patients with UM.…”

Section: Analysis Of S100b and Mia Concentrations Dependent On Absenc...mentioning

confidence: 99%

Threshold Optimization for Tumor Markers S100b and MIA in Uveal Melanoma – A Single Center Analysis

GLASER,

PETZOLD,

WESSELY

et al. 2023

Anticancer Res

View full text Add to dashboard Cite

Background/Aim: Uveal melanoma (UM) is the most common malignant tumor of the eye in adults. Metastases develop in 50% of the patients, predominantly in the liver. In UM, the cut-off concentrations of the bloodbased tumor markers S100b and MIA are inconclusive. Patients and Methods: In this retrospective monocenter study, we statistically evaluated 1,878 S100b and 1,768 MIA measurements in 244 patients with UM from 2011-2020. Threshold optimization was performed using receiver operating characteristic (ROC) curves. Results: A total of 171 patients with non-metastatic UM (nmUM) and 73 patients with metastatic UM (mUM) showed no differences in sex, age at diagnosis or the affected eye. In mUM, 80% of the patients developed metastases to the liver at a median of 46 months after initial diagnosis. The sensitivity and specificity of S100b was 16.10% and 94.52%, and that of MIA was 31.86% and 81.42%, respectively. ROC curves revealed poor values for the area under the curve of 0.57 for S100b and 0.55 for MIA. The optimal cut-off concentration to detect metastases was 0.14 μg/l for S100b and 17.4 ng/ml for MIA. With at least one tumor marker elevated, optimized sensitivity was 20.40% and specificity 96.76%. Conclusion: Current thresholds for S100b and MIA in UM are not able to detect early metastatic disease and require additional diagnostics to clarify false positive results. Threshold optimization considering both S100b and MIA results in a better diagnostic validity with an acceptable specificity and a poor sensitivity. Highly sensitive blood-based and imaging methods to detect metastases early in UM are urgently needed.

show abstract

Section: Analysis Of S100b and Mia Concentrations Dependent On Absenc...mentioning

confidence: 99%

Threshold Optimization for Tumor Markers S100b and MIA in Uveal Melanoma – A Single Center Analysis

GLASER,

PETZOLD,

WESSELY

et al. 2023

Anticancer Res

View full text Add to dashboard Cite

show abstract

“…Survival rates of MUM have not been improved over years [ 6 , 25 ], and there is still a lack of standardized therapeutic regimens [ 26 ]. Consequently, combination strategies which intend to overcome this resistance are urgently needed.…”

Section: Introductionmentioning

confidence: 99%

Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?

Blomen

Kött

Hartung

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Uveal Melanoma (UM) is a rare disease; however, it is the most common primary intraocular malignant tumor in adults. Hematogenous metastasis, occurring in up to 50% of cases, mainly to the liver (90%), is associated with poor clinical course and treatment failure. In contrast to dramatic benefits of immunotherapy in many tumor entities, as seen in cutaneous melanoma, immune checkpoint inhibitors (ICI) do not achieve comparable results in Metastatic UM (MUM). The aim of this study was to investigate whether the combination of ICI with liver-directed therapies provides a potential survival benefit for those affected. This retrospective, single-center study, including n = 45 patients with MUM, compared the effect of combining ICI with liver-directed therapy (“Cohort 1”) with respect to standard therapies (“Cohort 2”) on overall survival (OS). Our results revealed a significant survival difference between Cohort 1 (median OS 22.5 months) and Cohort 2 (median OS 11.4 months), indicating that this combination may enhance the efficacy of immunotherapy and thus provide a survival benefit. There is an urgent need for randomized, prospective trials addressing the combination of liver-directed therapies and various strategies of immunotherapy (such as ICI; IMCgp100; personalized vaccines) in order to establish regimens which finally improve the prognosis of patients with MUM.

show abstract

Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment

Petzold

Steeb

Wessely

et al. 2023

Cancer Treatment Reviews

View full text Add to dashboard Cite

Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)

Cited by 3 publications

References 22 publications

Threshold Optimization for Tumor Markers S100b and MIA in Uveal Melanoma – A Single Center Analysis

Threshold Optimization for Tumor Markers S100b and MIA in Uveal Melanoma – A Single Center Analysis

Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?

Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment

Contact Info

Product

Resources

About